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Background: In Uganda, treatment of clinical malaria and intermittent preventive treatment with sulphadoxine-
pyrimethamine (SP) are common during pregnancy. As a result, both formal and informal reports from antenatal
sources suggest possible misuse of SP for malaria treatment among pregnant women. The objective of this study
was to investigate anti-malarial drug use patterns among women who had recently suffered malaria illness before
and during pregnancy.
Methods: A cross-sectional study in which a structured questionnaire (interviewer-administered) was used to collect
data from pregnant women attending an urban antenatal clinic. Details of medicines used to treat malaria episodes
suffered before and during pregnancy were captured. A first order Markov probability model was used to estimate
probabilities of transitioning between treatment choices made before and during pregnancy. Logistic regression
was used to explore whether demographic and obstetric characteristics were associated with transition patterns.
Results: Seven hundred women were interviewed among whom 428 had suffered malaria in both instances. Three
hundred thirty of these could recall the medicines used in both instances. Women who used ACT/QNN (correct
choice) before pregnancy had higher probabilities of transitioning to SP than staying on ACT/QNN during pregnancy
(0.463 versus 0.451). Access of medicines from private outlets (clinics and pharmacies) were more than nine times
predictive of receiving correct medicines (p=0.035 and p=0.039 respectively). Access of medicines from clinics
was 5.9 times protective against receiving SP for malaria treatment (p=0.033). Among those who used SP before
pregnancy, there was a 0.75 probability of staying on it during pregnancy. None of the factors explored could
explain this observation.
Conclusion: Use of SP for malaria treatment is common during pregnancy. This may be contributing to adverse
pregnancy outcomes. Antenatal care providers should endeavour to emphasize the distinction between treatment
and prevention of malaria during pregnancy.
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Among adult populations in sub-Saharan Africa, preg-
nant women are disproportionately affected by malaria.
The World Health Organization (WHO) recommends a
combination of measures to mitigate the adverse impact
of malaria during pregnancy. These include; use of
insecticide-treated bed nets, early case detection and
treatment (with an effective anti-malarial medicine) as
well as intermittent preventive treatment during preg-
nancy (IPTp) [1]. Each year, more than thirty million
pregnancies at risk of malaria occur in Africa [2] and of
these, Uganda accounts for a considerable proportion
mainly for two reasons; First, Ugandan women have the
third highest fertility rate in the world [3]. Secondly,
malaria is endemic in 95% of Uganda’s geographical
territory which include places known to have some of
the highest transmission rates ever recorded [4]. While
recent efforts to control malaria in Uganda have regis-
tered remarkable gains, this dual burden most likely
predisposes Ugandan women to high tendencies to con-
sume anti-malarial medicines.
Whereas sulphadoxine-pyrimethamine (SP) remains
the most appropriate drug for IPTp, the WHO recom-
mends artemisinin-based combination therapy (ACT) as
first-line treatment for uncomplicated malaria in the
second and third trimesters of gestation [1]. ACT is
however contraindicated in the first trimester of gesta-
tion [5] owing to limited safety data on artemisinins in
early pregnancy. Instead, oral quinine (QNN) plus clin-
damycin given for seven days, is the recommended first-
line treatment for malaria in this period [1]. The treat-
ment policy for malaria during pregnancy in Uganda is
largely similar to that of the WHO [6]. However, effect-
ive treatment in the first trimester is often challenging as
clindamycin may not be affordable or readily available.
This has led to common use of QNN monotherapy with
poor adherence due to the relatively long treatment
course (7 days) coupled with numerous side effects [7].
Furthermore, contrary to current guidelines, presumptive
treatment of malaria remains high in many resource-
limited settings [8,9]. This practice has persisted due to
continuous challenges with access and delivery of reliable
diagnostic services [10]. Needless to say, presumptive
treatment leads to wasteful consumption of anti-malarial
medicines [9,11] and significantly delays treatment of
other febrile illnesses [11,12] and as a result, may portend
adverse consequences.
Whereas antenatal care (ANC) clinics have the poten-
tial to effectively serve as delivery platforms for malaria
control interventions in pregnancy, access to quality
ANC remains a challenge in many African settings
[13-15]. The Uganda Reproductive Health Policy recom-
mends a minimum of four ANC visits in which a
complete package can be delivered [16]. A woman witha normal pregnancy is expected to make at least one
visit in each of the first and second trimesters and two
visits in the third trimester. During these visits, women
are supposed to receive malaria control interventions
such as insecticide-treated bed nets, SP- IPTp, and most
importantly, knowledge and awareness information on
malaria prevention and its treatment. However, both
formal [17,18] and informal reports from pregnant
women in recent times continue to suggest SP misuse
for malaria treatment. The broad objective of this study
was to investigate the knowledge and practice gaps asso-
ciated with malaria treatment among Ugandan pregnant
women. This report presents insights from anti-malarial
drug use patterns among a population of Ugandan
women attending an urban antenatal clinic.
Methods
Study design
This was a cross-sectional study that employed quantita-
tive methods of data collection and analysis. Exit inter-
views were used to collect data from pregnant women
attending ANC at Mulago Hospital. Data for this study
was obtained as part of a larger cross-sectional study on
malaria, IPTp and anti-malarial drug use among Ugandan
women, some of which was recently published [19].
Study site and study population
Mulago Hospital is a 1,500 bed complex located in
Kampala, the capital and commercial centre of Uganda.
This is a public facility that serves as Uganda’s national
referral and teaching hospital. In addition to offering a
wide range of specialized care, the hospital runs special-
ized outpatient clinics on week days. Most outpatients
come from the urban and peri-urban communities of
Kampala and the neighbouring districts of Mukono,
Wakiso and Mpigi. The majority of outpatients visiting
the hospital tend to come from low and middle income
families who prefer to utilize the hospital’s free services.
The hospital runs two ANC clinics located at Old- and
New Mulago complexes. The two clinics offer general
(routine) and referral ANC services respectively. The
study was conducted at the Old Mulago clinic because it
was the first point of call for all pregnant women seeking
ANC at the hospital.
Research instrument
A structured questionnaire developed from our objec-
tives based on the conceptual model proposed by Ribera
et al. [20], was used to collect data from participants.
Items covered addressing the present objective included
a recall of any malaria episode prior to the current preg-
nancy including the treatment thereof. In addition, if the
women had ever suffered from malaria during pregnancy
(current or recent pregnancy), the names and sources of
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care was taken to distinguish between its use for treat-
ment of symptomatic malaria and its use as IPTp (the
latter is standard care for all women attending ANC in
Uganda [6]). Additional data collected included partici-
pant’s age, highest education level attained, parity (gesta-
tional age ≥ 28 weeks) and number of ANC visits in their
most recent pregnancy. The complete questionnaire is
available as Additional file 1. Prior to data collection, the
questionnaire was pre-tested on fifty women from the
same clinic. This allowed the research team to cater for
all possible responses as well as standardize questions so
as to ensure internal validity. Detailed data collection
methods have been recently published [19].
Sample size determination and selection criteria
Using the survey formula of Cochran [21], a minimum
sample size of 303 participants was required based on
the following parameter estimates; a 5% level of preci-
sion, a standard normal deviate (Zα) of 1.96 (for a confi-
dence level of 95%) and a 27% variability level for
women who develop malaria during pregnancy based on
a recent study conducted in a similar setting [22]. How-
ever, in order to qualify for the present analysis, partici-
pants had to have experienced malaria before as well as
during pregnancy. Therefore, women were consecutively
approached without exclusion, and invited to participate
in the study. This strategy allowed for random selection
and attainment of the desired number of participants.
Recruitment and data collection
Recruitment and data collection for the entire study
was done over three weeks in August 2013. Pregnant
women leaving the consultation rooms were consecu-
tively approached and invited to participate. Three
female students of nursing were trained and assisted in
this exercise. On each clinic day, data collection begun
at 09:00 and ended at 13:00 hours. Each research assist-
ant administered the questionnaire to an average of 15
pregnant women per day, with each interview lasting
between ten to fifteen minutes. The interviewers were
free to ask additional specific questions so as to satisfy
themselves that anti-malarial medicines were not being
confused with other routine ANC medications. Com-
munication was either in English or a local vernacular
language (whichever was convenient for individual
women). Whilst in the clinic, all completed question-
naires were scrutinized by the investigators so as to en-
sure correctness and completeness of records before
they were filed.
Ethical considerations
The study protocol received ethical approval from the
hospital’s research and ethics committee (Approval Ref.No. MREC 397) as well as the Uganda National Council
for Science and Technology (UNCST). Oral consent was
obtained from each participant prior to interviews. Con-
venience and confidentiality were observed by interview-
ing each participant in privacy within the clinic premises.
Data management and statistical analysis
Data was coded, double entered and validated in Epi-
Data® software [23] from where it was exported to R
statistical computing software for analysis [24]. In order
to analyse drug use patterns for malaria treatment before
and during pregnancy, a Markov probability model was
proposed. Three main transition states were identified
and coded as follows:
State 1-ACT/QNN: Either of these medicines was
considered a correct treatment hence the two were
combined (since we were unable to determine the actual
gestational age at which malaria episode occurred).
State 2-SP: This was considered the misguided choice
(arising out of misconception about its indication,
possibly due to confusion with its common use as
IPTp).
State 3-OTHERS: Consisting of all other incorrect
medicines that were mentioned, including chloroquine,
antibiotics and herbal remedies.
In order to construct the probability model presented
in Figure 1, two assumptions were made namely; i) a
constant time interval for each woman, between malaria
episodes suffered before and during pregnancy, and ii)
each medicine was considered used in its rightful dose
and duration at all times. Furthermore, Anderson and
Goodman’s maximum likelihood ratio criterion [25] was
used to test for the Markov property in the data prior to
modelling. The null hypothesis was independence of
medicine choice before and during pregnancy, while the
alternative hypothesis was that choices exhibited partial
dependence. With a chi square value of 51 against 4
degrees of freedom, the null hypothesis was rejected
(p < 0.000). Thus, the data was analysed using a first
order Markov model. Transition probabilities were esti-
mated by a simple non-parametric count method. Vari-
ables such as ‘source of medicine’ as well as demographic
and obstetric characteristics were investigated as possible
predictors of transitioning between states. Multivariate
logistic regression analysis of covariate dependence [26]
was performed on six transition scenarios which were of
interest (see Figure 1) namely;
i. Use of ACT/QNN both before and during
pregnancy (1→ 1),
ii. Use of ACT/QNN when not pregnant, then
transitioning to SP when pregnant (1→ 2),
Figure 1 Markov probability model showing treatment choice transitions before and during pregnancy.
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pregnancy (2→ 2),
iv. Use of SP when not pregnant and transitioning to
ACT/QNN when pregnant (2→ 1),
v. Use of OTHERS when not pregnant and
transitioning to SP when pregnant (3→ 2)
vi. Use of OTHERS when not pregnant then ACT/QNN
when pregnant (3→ 1).
Odds ratios were computed for each transition with
statistical significance set at p ≤ 0.05 at the 95% confi-
dence level.
Results
Demographic characteristics of respondents
Seven hundred respondents were interviewed in order to
identify 428 women who had suffered malaria before as
well as during pregnancy. Three hundred and thirty of
these could correctly recall the medicines used to treat
the two malaria episodes and thus constituted the sam-
ple for the present analysis. Median age in this group
was 25 years (min. 19, max. 41). Most had completed
primary (36.1%) or basic secondary (25.2%) education.
Only 24.5% had attained advanced secondary educationor other higher qualifications while 14.2% had never
attended (or failed to complete) primary education.
First- and second-time mothers respectively, comprised
16.4% and 48.4% of the sample, while women who had
experienced higher number of pregnancies comprised
35.1% of the sample. Excluding first-time mothers, 82.1%
of women had attended between 3–7 ANC visits during
their most recent pregnancy. Only 13.6% had attended
1–2 times while 4.3% never attended ANC in their most
recent pregnancy. When asked to mention the sources
of medicines used for treatment of malaria episodes suf-
fered during pregnancy, 50.0% (n=165) reported acces-
sing medicines from a private clinic while 29.1%
accessed from a hospital. Other sources of medicines
were public health centres 8.5%, private pharmacies
8.8%, and community drug shops 3.6%.
State occupancy and transition probabilities for
medicines used before and during pregnancy
Overall, ACT/QNN were the most commonly used
treatment before pregnancy while SP was most com-
monly used during pregnancy. This was true regardless
of the medicines used before pregnancy. Table 1 pre-
sents state prevalence and probability estimates for use
Table 1 State prevalence and transition probability matrix for anti-malarial treatments used before and during
pregnancy
State prevalences (%) n=330 Transition probabilities
Before pregnancy During pregnancy → ACT/QNN → Others → SP
ACT/QNN→ 74.5 41.9 0.451 0.085 0.463
Others→ 12.1 7.9 0.425 0.025 0.550
SP→ 13.3 51.2 0.159 0.091 0.750
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Figure 1 presents the transition probability estimates
(from Table 1) in form of a Markov model diagram.
Among women who used ACT/QNN before pregnancy,
there was a higher probability of switching to SP
(p=0.463) than remaining on ACT/QNN (p=0.451) during
pregnancy. Among those who used SP before pregnancy,
there was a higher probability of remaining on SP
(p=0.75) than switching to ACT/QNN (p=0.159) during
pregnancy. Among those who used ‘OTHERS’ before
pregnancy, there was a higher probability of switching
to SP (p=0.55) than switching to ACT/QNN (p=0.425).
Factors determining treatment choice transitions during
pregnancy
Of the six transition scenarios for which multivariate
analysis was performed, significant findings were seen in
only two scenarios; 1: use of ACT/QNN in both in-
stances, before and during pregnancy (1→ 1), and 2: use
of ACT/QNN before pregnancy then switching to SP
during pregnancy (1→ 2). Of all predictor variables
investigated, only ‘source of medicine’ significantly pre-
dicted transitions in the two scenarios. Women who
used ACT/QNN prior to pregnancy were 9.8 and 11.4
times likely to stay on it if the medicine was accessed
from a private clinic or private pharmacy respectively
(Table 2). Among women who used ACT/QNN before
pregnancy, accessing medicines from a private clinic was
5.9 times protective against switching to SP during preg-
nancy. A similar trend was noticed with all other sources
of medicines although they did not reach statistical sig-
nificance (see Table 2).
Discussion
This study used a transition probability model to show
changes in malaria treatment patterns among pregnant
women in Uganda. Women were more likely to use SP
than ACT/QNN, to treat reported episodes of malaria
during pregnancy. The prevalence and probability pat-
terns revealed here show that women (or their treatment
providers) consciously chose to use SP for malaria treat-
ment, highlighting possible existence of confusion about
its role (indication) during pregnancy. High levels of
awareness about SP as an anti-malarial drug coupled with
low knowledge about its indication during pregnancy hasbeen previously reported in this study population [19].
This critical knowledge deficit may be attributed to the
low education levels considering that more than half of
the women had received limited (primary) or no formal
education. It is, therefore, probable that they did not easily
comprehend the distinction between treatment and
prevention of malaria and the drugs thereof. Because
patients in developing countries most often trust and
follow malaria treatment advice offered by health
workers [27], these results may be a reflection of health
workers’ lack of focussed malaria treatment informa-
tion. Alternatively, health workers may be delivering
this information in a manner that is inappropriate to re-
cipients’ needs, given their low literacy and low know-
ledge base, thus leaving them ‘half-baked’.
Many previous studies have highlighted the high rates
of self-medication and informal treatment-seeking be-
haviour in Uganda [27-30]. In light of these consider-
ations, the present findings raise two disturbing concerns;
first, unless SP-IPTp is administered under the strict
supervision of a health worker, women who do not per-
ceive themselves as ill with malaria (as at routine ANC
visits), are unlikely to take SP-IPTp by themselves. As
such, questions as to whether pregnant women comply
with unsupervised intake (of SP-IPTp) remain valid [19].
Secondly, SP lacks efficacy against clinical malaria. Its use
for malaria treatment may, therefore, be associated with
high risks of treatment failure and the consequences
thereof. These concerns may not be far-fetched consider-
ing the high awareness about SP, its inexpensiveness and
wide availability in many drug outlets within Uganda,
often with inadequate regulatory oversight. It is, therefore,
possible that consequences of inappropriate use of
SP significantly contribute to the high incidences of
poor pregnancy outcomes in Uganda. In a recent study
from Mukono district (Uganda), Mbonye et al. showed
a high prevalence of self-medication with SP among
cotrimoxazole-taking HIV positive pregnant women
presenting with a febrile illness [17]. Clearly, such prac-
tices underscore the misconception about SP as a treat-
ment for malaria during pregnancy.
As with many studies from Uganda and elsewhere
[29-33], private drug outlets were an important source
of anti-malarial medicines in this study. This may be due
to their common location within residential areas where
Table 2 Multivariate regression analysis of predictors of transitioning between malaria treatments received before and
during pregnancy
Variables Log odds Std. error OR* (C.I.) 1/OR† p-value
Transition scenario ACT/QNN before and during pregnancy (1→ 1)
Constant −1.298 1.461 0.273 0.374
Age −0.032 0.043 0.969 (0.89–1.05) 1.03 0.456
Education level 0.049 0.119 1.05 (0.83–1.34) 0.678
Parity −0.107 0.135 0.899 (0.69–1.68) 1.11 0.423
No. of ANC visits 0.011 0.098 1.011 (0.83–1.23) 0.913
Private clinic 2.286 1.085 9.84 (1.69–18.6) 0.035
Pharmacy 2.429 1.178 11.35 (1.53–23.8) 0.039
Public Health center 1.195 1.170 3.3 (0.44–6.8) 0.307
Hospital 2.009 1.098 7.46 (1.24–14.3) 0.067
Transition scenario ACT/QNN to SP before and during pregnancy (1→ 2)
Constant 0.267 1.267 1.31 (0.11–18.13) 0.833
Age 0.021 0.043 1.02 (0.94–1.11) 0.626
Education level −0.038 0.119 1.04 (0.76–1.22) 0.754
Parity 0.169 0.134 1.18 (0.91–1.55) 0.208
No. of ANC visits 0.089 0.098 1.09 (0.90–1.33) 0.359
Private clinic −1.776 0.834 0.169 (0.02–0.75) 5.9 0.033
Pharmacy −1.684 0.954 0.186 (0.02–1.08) 5.4 0.078
Public Health center −1.504 0.915 0.222 (0.03–1.19) 4.5 0.10
Hospital −1.506 0.850 0.221 (0.03–1.02) 4.4 0.076
*OR: odds ratio, †inverse operation applied to OR estimates less than 1 only.
boldface figures indicate statistical significance at p less than 0.05 at the 95% confidence level.
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ness. Interestingly in this study, access of anti-malarial
medicines through private drug outlets appeared to
guard against inappropriate use of SP. This finding is
contrary to past studies that have suggested that treat-
ment decisions among private or informal health care
providers were often irrational, driven more by profit
motives than clients’ interests [34]. Despite the fact that
we did not determine actual prescribers of the medicines
reported in this study, the possibility of self-treatment
cannot be under-estimated since the purchase of medi-
cines without a prescription is not uncommon in this
society as cited above. Evidence from previous studies
suggests that both patients and prescribers alike, con-
tribute to the culture of irrational drug-use. In the study
from Mukono cited above, 10.9% of parasite-confirmed
and 48.6% of parasite-negative pregnant women received
SP as treatment from health centre staff [17]. Therefore,
both parties may be responsible for the irrational pattern
of SP use observed in this study.
The findings from this study may have two important
limitations, namely respondents’ ability to distinguish
malaria from other illnesses as well as recall bias to do
with event details. Whereas nearly all data collected in
this study reflected events that happened more thanone month earlier, malaria is not just an event in this
society, rather, it is a very common experience that re-
spondents easily relate with. As such, many adults, es-
pecially household heads (as in this case) have vivid
ideas on its symptoms and popular remedies. There-
fore, accurate memory about the details around malaria
episodes were likely to be high. Furthermore, only
respondents who could clearly identify anti-malarial
medicines by name or description were included in this
analysis. Ninety-eight potential respondents who failed
to clearly articulate names or descriptions of the medi-
cines used in both states were excluded. Thus, the
above limitations were significantly minimized within
the limits of the cross-sectional study design and the
research tools employed.
Conclusion
This study highlights the inappropriate use of SP for
malaria treatment among pregnant women in Uganda.
In order to address this problem and improve malaria
treatment during pregnancy, health workers should at all
times endeavour to provide appropriate information on
malaria treatment. Additional emphasis should be placed
on the distinction between prevention and treatment of
clinical malaria during pregnancy.
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Additional file 1: Knowledge and experiences with malaria and
sulphadoxine-pyrimethamine (Fansidar) among pregnant women at
Mulago referral hospital, Kampala. This is a three-part, twenty-item, research
instrument (questionnaire) used to collect data on knowledge and
experiences with malaria and anti-malarial drug use among Ugandan
pregnant women.
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